Innovation and Value Initiative

Moving beyond academic rhetoric is the bold step needed to make a wider field of value flowers take root and flourish.

Assessing the value of novel therapies has been challenging and controversial using existing methods, pointing to the need for continued exploration of new approaches.

There are shortcomings in the ways we have approached value assessment to date, writes the executive director of the Innovation and Value Initiative.

IVI seeks comment on its new NSCLC model through April 1, 2019.

Despite the increasing focus on the concept of “value” in healthcare, there is lack of consensus on a definition of value. While patient-centricity has been a steady refrain in healthcare, we question whether the values, needs, and preferences of patients have been meaningfully incorporated into value assessments thus far.

The current environment for healthcare value assessment seems to mirror American politics: a rush to the extreme at a time when collaboration in the sensible middle is most needed.

As healthcare innovation accelerates, it’s important to have scientific methods and begin to move towards a more inclusive and transparent approach to measuring value—one that acknowledges diversity among patients’ characteristics, preferences, and related treatment effects.